Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
The Difficulties of Cloning a CEO - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Justice Dept reportedly may file charges in its generic-drug probe by year-end
Teva Agrees to Purchase Rimsa in $2.3 Billion Deal
Teva Considering Cutting up to 10,000 Jobs: Bloomberg
Teva: Now What? | Barron's
Teva Agrees to Settle Opioid Lawsuits for as Much as $4.25 Billion - WSJ
Teva looks to sell generics in China through joint venture with Guangzhou Pharma: Bloomberg | Fierce Pharma
Teva Cites 'Havoc' as It Takes Drug Label Spat to Supreme Court (1)
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva Pharmaceuticals - Wikipedia
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Stares Into Abyss as It Slashes Forecast, Dividends - Bloomberg
Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva Offers Drugs Valued at $23 Billion to End Opioid Suits - Bloomberg
HSBC downgrades Teva on uncertainty surrounding DOJ's reported generic drug investigation
